Search Results - "Freeman, Daniel J"

Optimizing oncolytic virotherapy in cancer treatment by Harrington, Kevin, Freeman, Daniel J., Kelly, Beth, Harper, James, Soria, Jean-Charles

“…In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently seen as a potential therapeutic option for patients with cancer who…”
Get full text

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer by AMADO, Rafael G, WOLF, Michael, PATTERSON, Scott D, CHANG, David D, PEETERS, Marc, VAN CUTSEM, Eric, SIENA, Salvatore, FREEMAN, Daniel J, JUAN, Todd, SIKORSKI, Robert, SUGGS, Sid, RADINSKY, Robert

“…Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer…”
Get full text

Head-mounted central venous access during optical recordings and manipulations of neural activity in mice by Liu, Christine, Freeman, Daniel J., Lammel, Stephan

“…Establishing reliable intravenous catheterization in mice with optical implants allows the combination of neural manipulations and recordings with rapid,…”
Get full text

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer by Freeman, Daniel J, McDorman, Kevin, Ogbagabriel, Selam, Kozlosky, Carl, Yang, Bing-Bing, Doshi, Sameer, Perez-Ruxio, Juan Jose, Fanslow, William, Starnes, Charlie, Radinsky, Robert

“…Successful treatment of solid tumors relies on the ability of drugs to penetrate into the tumor tissue. We examined the correlation of panitumumab (an…”
Get full text

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer by Mendell, Jeanne, Freeman, Daniel J., Feng, Wenqin, Hettmann, Thore, Schneider, Matthias, Blum, Sabine, Ruhe, Jens, Bange, Johannes, Nakamaru, Kenji, Chen, Shuquan, Tsuchihashi, Zenta, von Pawel, Joachim, Copigneaux, Catherine, Beckman, Robert A.

“…During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible…”
Get full text

PTEN Regulates Mdm2 Expression through the P1 Promoter by Chang, Chun-Ju, Freeman, Daniel J, Wu, Hong

“…MDM2 is an oncoprotein that controls tumorigenesis through both p53-dependent and -independent mechanisms. Mdm2 mRNA level is transcriptionally regulated by…”
Get full text

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor by Freeman, Daniel J, Bush, Tammy, Ogbagabriel, Selam, Belmontes, Brian, Juan, Todd, Plewa, Cherylene, Van, Gwyneth, Johnson, Carol, Radinsky, Robert

“…Epidermal growth factor receptor (EGFR) kinase domain mutations cause hyperresponsiveness to ligand and hypersensitivity to small-molecule tyrosine kinase…”
Get full text

A comparability study of 5 commercial KRAS tests by Oliner, Kelly, Juan, Todd, Suggs, Sid, Wolf, Michael, Sarosi, Ildiko, Freeman, Daniel J, Gyuris, Tibor, Baron, Will, Bakker, Andreas, Parker, Alex, Patterson, Scott D

“…Activating mutations in the KRAS gene occur frequently in human tumors, including colorectal carcinomas; most mutations occur in codons 12 and 13. Mutations in…”
Get full text

Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract Cancer by Kruser, Tim J., M.D, Armstrong, Eric A., M.S, Ghia, Amol J., M.D, Huang, Shyhmin, Ph.D, Wheeler, Deric L., Ph.D, Radinsky, Robert, Ph.D, Freeman, Daniel J., Ph.D, Harari, Paul M., M.D

“…Purpose To examine the interaction between panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, and radiation in head-and-neck…”
Get full text

Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models by Boedigheimer, Michael J, Freeman, Daniel J, Kiaei, Panteha, Damore, Michael A, Radinsky, Robert

“…Abstract Background Epidermal growth factor receptor (EGFR)-targeted agents have demonstrated clinical benefit in patients with cancer. Identifying…”
Get full text

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 + Activated T Cells by Dovedi, Simon J, Elder, Matthew J, Yang, Chunning, Sitnikova, Suzanne I, Irving, Lorraine, Hansen, Anna, Hair, James, Jones, Des C, Hasani, Sumati, Wang, Bo, Im, Seock-Ah, Tran, Ben, Subramaniam, Deepa S, Gainer, Shelby D, Vashisht, Kapil, Lewis, Arthur, Jin, Xiaofang, Kentner, Stacy, Mulgrew, Kathy, Wang, Yaya, Overstreet, Michael G, Dodgson, James, Wu, Yanli, Palazon, Asis, Morrow, Michelle, Rainey, Godfrey J, Browne, Gareth J, Neal, Frances, Murray, Thomas V, Toloczko, Aleksandra D, Dall'Acqua, William, Achour, Ikbel, Freeman, Daniel J, Wilkinson, Robert W, Mazor, Yariv

“…The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events…”
Get more information

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer by Amado, Rafael G, Wolf, Michael, Peeters, Marc, Van Cutsem, Eric, Siena, Salvatore, Freeman, Daniel J, Juan, Todd, Sikorski, Robert, Suggs, Sid, Radinsky, Robert, Patterson, Scott D, Chang, David D

“…Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer…”
Get full text

Azole-based inhibitors of AKT/PKB for the treatment of cancer by Zeng, Qingping, Allen, John G., Bourbeau, Matthew P., Wang, Xianghong, Yao, Guomin, Tadesse, Seifu, Rider, James T., Yuan, Chester C., Hong, Fang-Tsao, Lee, Matthew R., Zhang, Shiwen, Lofgren, Julie A., Freeman, Daniel J., Yang, Suijin, Li, Chun, Tominey, Elizabeth, Huang, Xin, Hoffman, Douglas, Yamane, Harvey K., Fotsch, Christopher, Dominguez, Celia, Hungate, Randall, Zhang, Xiaoling

“…Through a combination of screening and structure-based rational design, we have discovered a series of N…”
Get full text

A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer by Crawford, Jeffrey, Swanson, Paul, Schwarzenberger, Paul, Sandler, Alan, Prager, Diane, Zhang, Kathy, Freeman, Daniel J, Johnson, Carol W, Krishnan, Kartik, Johnson, David

“…This two-part phase 2 study evaluated the efficacy and safety of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, combined…”
Get more information

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms by Freeman, Daniel J., Li, Andrew G., Wei, Gang, Li, Heng-Hong, Kertesz, Nathalie, Lesche, Ralf, Whale, Andrew D., Martinez-Diaz, Hilda, Rozengurt, Nora, Cardiff, Robert D., Liu, Xuan, Wu, Hong

“…We show in this study that PTEN regulates p53 protein levels and transcriptional activity through both phosphatase-dependent and -independent mechanisms. The…”
Get full text

Association of K- ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone by Freeman, Daniel J, Juan, Todd, Reiner, Maureen, Hecht, J. Randolph, Meropol, Neal J, Berlin, Jordan, Mitchell, Edith, Sarosi, Ildiko, Radinsky, Robert, Amado, Rafael G

“…Abstract Background Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K- ras , BRAF , and…”
Get full text

Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability by Stec, Markian M, Andrews, Kristin L, Booker, Shon K, Caenepeel, Sean, Freeman, Daniel J, Jiang, Jian, Liao, Hongyu, McCarter, John, Mullady, Erin L, San Miguel, Tisha, Subramanian, Raju, Tamayo, Nuria, Wang, Ling, Yang, Kevin, Zalameda, Leeanne P, Zhang, Nancy, Hughes, Paul E, Norman, Mark H

“…N-(6-(6-Chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide (1) is a potent and efficacious inhibitor of PI3Kα and mTOR in vitro…”
Get full text

Selective Class I Phosphoinositide 3‑Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511 by Norman, Mark H, Andrews, Kristin L, Bo, Yunxin Y, Booker, Shon K, Caenepeel, Sean, Cee, Victor J, D’Angelo, Noel D, Freeman, Daniel J, Herberich, Bradley J, Hong, Fang-Tsao, Jackson, Claire L. M, Jiang, Jian, Lanman, Brian A, Liu, Longbin, McCarter, John D, Mullady, Erin L, Nishimura, Nobuko, Pettus, Liping H, Reed, Anthony B, Miguel, Tisha San, Smith, Adrian L, Stec, Markian M, Tadesse, Seifu, Tasker, Andrew, Aidasani, Divesh, Zhu, Xiaochun, Subramanian, Raju, Tamayo, Nuria A, Wang, Ling, Whittington, Douglas A, Wu, Bin, Wu, Tian, Wurz, Ryan P, Yang, Kevin, Zalameda, Leeanne, Zhang, Nancy, Hughes, Paul E

“…The phosphoinositide 3-kinase family catalyzes the phosphorylation of phosphatidylinositol-4,5-diphosphate to phosphatidylinositol-3,4,5-triphosphate, a…”
Get full text

Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases by Smith, Adrian L, D’Angelo, Noel D, Bo, Yunxin Y, Booker, Shon K, Cee, Victor J, Herberich, Brad, Hong, Fang-Tsao, Jackson, Claire L. M, Lanman, Brian A, Liu, Longbin, Nishimura, Nobuko, Pettus, Liping H, Reed, Anthony B, Tadesse, Seifu, Tamayo, Nuria A, Wurz, Ryan P, Yang, Kevin, Andrews, Kristin L, Whittington, Douglas A, McCarter, John D, Miguel, Tisha San, Zalameda, Leeanne, Jiang, Jian, Subramanian, Raju, Mullady, Erin L, Caenepeel, Sean, Freeman, Daniel J, Wang, Ling, Zhang, Nancy, Wu, Tian, Hughes, Paul E, Norman, Mark H

“…A highly selective series of inhibitors of the class I phosphatidylinositol 3-kinases (PI3Ks) has been designed and synthesized. Starting from the dual…”
Get full text

Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold by Wurz, Ryan P., Liu, Longbin, Yang, Kevin, Nishimura, Nobuko, Bo, Yunxin, Pettus, Liping H., Caenepeel, Sean, Freeman, Daniel J., McCarter, John D., Mullady, Erin L., Miguel, Tisha San, Wang, Ling, Zhang, Nancy, Andrews, Kristin L., Whittington, Douglas A., Jiang, Jian, Subramanian, Raju, Hughes, Paul E., Norman, Mark H.

“…Phosphoinositide 3-kinase (PI3K) is an important target in oncology due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors. A…”
Get full text